Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2940781 | 0.95 | SCD (0.60) | SCDSCD5 | |
| SCHEMBL4099930 | 0.94 | SCD (0.58) | SCD | |
| SCHEMBL14870430 | 0.92 | SCD (0.55) | SCD | |
| SCHEMBL13870690 | 0.91 | SCD (0.54) | SCD | |
| SCHEMBL13870689 | 0.90 | SCD (0.53) | SCD | |
| SCHEMBL4093029 | 0.90 | SCD (0.54) | SCD | |
| SCHEMBL2949531 | 0.88 | SCD (0.52) | SCD | |
| SCHEMBL4093392 | 0.86 | SCD (0.64) | SCDSCD5 | |
| SCHEMBL2951420 | 0.84 | SCD (0.49) | SCD | |
| SCHEMBL13870683 | 0.84 | SCD (0.56) | SCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9358250-B2 | Methods of using SCD1 antagonists | GENENTECH, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-9358250-B2 | Methods of using SCD1 antagonists | GENENTECH, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-20090099200-A1 | Azacyclohexane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase | MERCK FROSST CANADA LTD. (CA) | 2009-04-16 | — | — | US | disclosed |
| US-20090099200-A1 | Azacyclohexane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase | MERCK FROSST CANADA LTD. (CA) | 2009-04-16 | — | — | US | disclosed |
| US-20090099200-A1 | Azacyclohexane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase | MERCK FROSST CANADA LTD. (CA) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099200-A1 | Azacyclohexane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase | SCD, SCD5, SREBF1 | SCD 1/4885SCD5 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.